{"downloaded": true, "htmlmade": false, "full": {"id": "30595526", "source": "MED", "pmid": "30595526", "pmcid": "PMC6391590", "fullTextIdList": {"fullTextId": "PMC6391590"}, "doi": "10.1016/j.ymthe.2018.12.005", "title": "Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.", "authorString": "Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H, Yamaoka M, Tachibana K, Hirato T, Sato Y.", "authorList": {"author": [{"fullName": "Okuyama T", "firstName": "Torayuki", "lastName": "Okuyama", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "National Centre for Child Health and Development, Tokyo 157-8535, Japan."}}}, {"fullName": "Eto Y", "firstName": "Yoshikatsu", "lastName": "Eto", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Advanced Clinical Research Centre & Asian Lysosome Storage Disorder Centre, Institute of Neurological Disorders, Kawasaki 215-0026, Japan."}}}, {"fullName": "Sakai N", "firstName": "Norio", "lastName": "Sakai", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Osaka University, Course of Health Science, Osaka 565-0871, Japan."}}}, {"fullName": "Minami K", "firstName": "Kohtaro", "lastName": "Minami", "initials": "K", "authorId": {"@type": "ORCID", "#text": "0000-0003-4698-6250"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "JCR Pharmaceuticals, Ashiya 659-0021, Japan."}}}, {"fullName": "Yamamoto T", "firstName": "Tatsuyoshi", "lastName": "Yamamoto", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "JCR Pharmaceuticals, Ashiya 659-0021, Japan."}}}, {"fullName": "Sonoda H", "firstName": "Hiroyuki", "lastName": "Sonoda", "initials": "H", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "JCR Pharmaceuticals, Ashiya 659-0021, Japan."}}}, {"fullName": "Yamaoka M", "firstName": "Mariko", "lastName": "Yamaoka", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "JCR Pharmaceuticals, Ashiya 659-0021, Japan."}}}, {"fullName": "Tachibana K", "firstName": "Katsuhiko", "lastName": "Tachibana", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "JCR Pharmaceuticals, Ashiya 659-0021, Japan."}}}, {"fullName": "Hirato T", "firstName": "Tohru", "lastName": "Hirato", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "JCR Pharmaceuticals, Ashiya 659-0021, Japan."}}}, {"fullName": "Sato Y", "firstName": "Yuji", "lastName": "Sato", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "JCR Pharmaceuticals, Ashiya 659-0021, Japan. Electronic address: sato-yuji@jcrpharm.co.jp."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0003-4698-6250"}}, "dataLinksTagsList": {"dataLinkstag": "altmetrics"}, "journalInfo": {"issue": "2", "volume": "27", "journalIssueId": "2780161", "dateOfPublication": "2019 Feb", "monthOfPublication": "2", "yearOfPublication": "2019", "printPublicationDate": "2019-02-01", "journal": {"title": "Molecular therapy : the journal of the American Society of Gene Therapy", "ISOAbbreviation": "Mol Ther", "medlineAbbreviation": "Mol Ther", "NLMid": "100890581", "ISSN": "1525-0016", "ESSN": "1525-0024"}}, "pubYear": "2019", "pageInfo": "456-464", "abstractText": "Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglycans, giving rise to multiple systemic and CNS symptoms. The currently available therapies, idursulfase and idursulfase beta, are ineffective against the CNS symptoms because they cannot pass the blood-brain barrier (BBB). A novel IDS fused with anti-human transferrin receptor antibody (JR-141) has been shown to penetrate the BBB and ameliorate learning deficits in model mice. This first-in-human study evaluated the pharmacokinetics, safety, and potential efficacy of JR-141 in 14 patients with MPS II. In a dose-escalation study performed in two patients, JR-141 plasma concentrations were dose dependent and peaked at 3\u00a0hr after initiation of each infusion, and no or only mild adverse reactions were exhibited. In a subsequent 4-week evaluation at two dose levels, the plasma concentration profiles were similar between the first and final administration, indicating no drug accumulation. Levels of heparan sulfate (HS) and dermatan sulfate (DS) were suppressed in both plasma and urine and HS levels were significantly decreased in cerebrospinal fluid. Two patients experienced some amelioration of neurocognitive and motor symptoms. These results suggest that the drug successfully penetrates the BBB and could have CNS efficacy.", "affiliation": "National Centre for Child Health and Development, Tokyo 157-8535, Japan.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Randomized Controlled Trial", "Journal Article"]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Blood-Brain Barrier"}, {"majorTopic_YN": "N", "descriptorName": "Animals"}, {"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Mucopolysaccharidosis II", "meshQualifierList": {"meshQualifier": {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Disease Models, Animal"}, {"majorTopic_YN": "N", "descriptorName": "Iduronate Sulfatase", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Receptors, Transferrin", "meshQualifierList": {"meshQualifier": {"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Antibodies", "meshQualifierList": {"meshQualifier": {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Cognition", "meshQualifierList": {"meshQualifier": {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Adolescent"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Child"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Young Adult"}, {"majorTopic_YN": "N", "descriptorName": "Enzyme Replacement Therapy"}]}, "keywordList": {"keyword": ["Blood brain barrier", "Dermatan sulfate", "CNS", "Cognitive impairment", "Clinical Trial", "Heparan Sulfate", "Hunter Syndrome", "Mucopolysaccharidosis Ii", "Enzyme-replacement Therapy", "Iduronate-2-sulfatase", "Anti-human Transferrin Receptor Antibody"]}, "chemicalList": {"chemical": [{"name": "Antibodies", "registryNumber": "0"}, {"name": "Iduronate Sulfatase", "registryNumber": "EC 3.1.6.13"}, {"name": "Receptors, Transferrin", "registryNumber": "0"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.ymthe.2018.12.005"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6391590"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6391590?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "23", "hasData": "N", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by-nc-nd", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "N", "dateOfCompletion": "2019-12-16", "dateOfCreation": "2019-01-01", "firstIndexDate": "2019-01-01", "fullTextReceivedDate": "2020-07-11", "dateOfRevision": "2020-03-09", "electronicPublicationDate": "2018-12-08", "firstPublicationDate": "2018-12-08", "embargoDate": "2020-02-06"}, "htmllinks": "https://europepmc.org/articles/PMC6391590", "abstract": "Hunter syndrome (mucopolysaccharidosis II [MPS II]), a deficiency of iduronate-2-sulfatase (IDS), causes an accumulation of glycosaminoglycans, giving rise to multiple systemic and CNS symptoms. The currently available therapies, idursulfase and idursulfase beta, are ineffective against the CNS symptoms because they cannot pass the blood-brain barrier (BBB). A novel IDS fused with anti-human transferrin receptor antibody (JR-141) has been shown to penetrate the BBB and ameliorate learning deficits in model mice. This first-in-human study evaluated the pharmacokinetics, safety, and potential efficacy of JR-141 in 14 patients with MPS II. In a dose-escalation study performed in two patients, JR-141 plasma concentrations were dose dependent and peaked at 3\u00a0hr after initiation of each infusion, and no or only mild adverse reactions were exhibited. In a subsequent 4-week evaluation at two dose levels, the plasma concentration profiles were similar between the first and final administration, indicating no drug accumulation. Levels of heparan sulfate (HS) and dermatan sulfate (DS) were suppressed in both plasma and urine and HS levels were significantly decreased in cerebrospinal fluid. Two patients experienced some amelioration of neurocognitive and motor symptoms. These results suggest that the drug successfully penetrates the BBB and could have CNS efficacy.", "Keywords": ["Blood brain barrier", "Dermatan sulfate", "CNS", "Cognitive impairment", "Clinical Trial", "Heparan Sulfate", "Hunter Syndrome", "Mucopolysaccharidosis Ii", "Enzyme-replacement Therapy", "Iduronate-2-sulfatase", "Anti-human Transferrin Receptor Antibody"], "pdflinks": "https://europepmc.org/articles/PMC6391590?pdf=render", "journaltitle": "Molecular therapy : the journal of the American Society of Gene Therapy", "authorinfo": ["Okuyama T", "Eto Y", "Sakai N", "Minami K", "Yamamoto T", "Sonoda H", "Yamaoka M", "Tachibana K", "Hirato T", "Sato Y"], "title": "Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial."}